Autoimmune response to C9orf72 protein in amyotrophic lateral sclerosis, 2025, Michaelis et al.

SNT Gatchaman

Senior Member (Voting Rights)
Staff member
Autoimmune response to C9orf72 protein in amyotrophic lateral sclerosis
Michaelis, Tanner; Lindestam Arlehamn, Cecilia S; Johansson, Emil; Frazier, April; Berry, James D; Cudkowicz, Merit; Goyal, Namita A; Fournier, Christina; Snyder, Allison; Kwan, Justin Y; Crook, Jody; Phillips, Elizabeth J; Mallal, Simon A; Ravits, John; Marder, Karen S; Sidney, John; Sulzer, David; Sette, Alessandro

Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease characterized by a progressive loss of motor neurons. Neuroinflammation is apparent in affected tissues, including increased T cell infiltration and activation of microglia, particularly in the spinal cord1,2. Autoimmune responses are thought to have a key role in ALS pathology, and it is hypothesized that T cells contribute to the rapid loss of neurons during disease progression3,4. However, until now there has been no reported target for such an autoimmune response.

Here we show that ALS is associated with recognition of the C9orf72 antigen, and we map the specific epitopes that are recognized. We show that these responses are mediated by CD4+ T cells that preferentially release IL-5 and IL-10, and that IL-10-mediated T cell responses are significantly greater in donors who have a longer predicted survival time.

Our results reinforce the previous hypothesis that neuroinflammation has an important role in ALS disease progression, possibly because of a disrupted balance of inflammatory and counter-inflammatory T cell responses4. These findings highlight the potential of therapeutic strategies aimed at enhancing regulatory T cells5, and identify a key target for antigen-specific T cell responses that could enable precision therapeutics in ALS.

Web | PDF | Nature | Open Access
 
Over the past few months I've been increasingly optimistic about the advances that might positively affect us. It's good to have hope, I think
 
Back
Top Bottom